These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17216846)

  • 1. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
    TreatmentUpdate; 2003; 15(3):4-5. PubMed ID: 17216846
    [No Abstract]   [Full Text] [Related]  

  • 2. Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
    Quercia R; Amiel C; Marechal Eda S; Lebrette MG; Thevenet S; Renaud S; Schneider V; Kara A; Guessant S; Pialoux G
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):389-90. PubMed ID: 16763531
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
    Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
    HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
    [No Abstract]   [Full Text] [Related]  

  • 6. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 7. Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
    Bongiovanni M; Tordato F
    Curr Med Chem; 2006; 13(23):2789-93. PubMed ID: 17073629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
    Clotet B; Negredo E; Girard PM; Youle M; Neubacher D
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):479-81. PubMed ID: 17622838
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
    Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
    Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 11. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160
    [No Abstract]   [Full Text] [Related]  

  • 12. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 13. Should tenofovir ever be used in association with didanosine?
    Diaz RS
    Braz J Infect Dis; 2005 Dec; 9(6):452-3. PubMed ID: 16410938
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinically stable treatment-experienced adults receiving tenofovir and didanosine.
    Di Biagio A; Beltrame A; Cenderello G; Ferrea G; De Maria A
    HIV Clin Trials; 2006; 7(1):10-5. PubMed ID: 16632460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate (Viread).
    Porche DJ
    J Assoc Nurses AIDS Care; 2002; 13(3):100-2. PubMed ID: 12064015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
    Riordan A; Judd A; Boyd K; Cliff D; Doerholt K; Lyall H; Menson E; Butler K; Gibb D;
    Pediatr Infect Dis J; 2009 Mar; 28(3):204-9. PubMed ID: 19209091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 19. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 20. [Conclusions. Tenofovir].
    Mallolas J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():62-4. PubMed ID: 19195439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.